MAP2K7 and neoplasm: The BRAFV600E oncoprotein constitutively activates pro-mitogenic RAF/MEK/ERK signaling (Davies et al, 2002; Fecher et al, 2008), and therapy with RAF inhibitors such as vemurafenib (Zelboraf®; PLX4032) causes tumor regression in many patients (Bollag et al, 2010; Chapman et al, 2011; Flaherty et al, 2012; Sosman et al, 2012).